Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisporivir for Hospitalised COVID-19 Patients
NCT04608214Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Alisporivir with Standard of Care (2 arms). Primary endpoint: Change in SARS-CoV-2 viral load in nasopharyngeal swabs at Day 7. Started Jan 2021; status: completed.
02
Drugs
alisporivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04608214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608214.